post_croi2015Seattle, WA, February 23-26, 2015

Exciting results from many studies in Pre-Exposure Prophylaxis, HIV and hepatitis C were presented at this year’s Conference on Retroviruses and Opportunistic Infections. For complete coverage by Project Inform from the 2015 CROI, read the March 2015 issue of PI Perspective, or click on the various articles below.

 

 

 

HIV CURE NEWS

New “Kick and Kill” HIV cure drug (TLR7 agonist) from Gilead shows promise

HIV PREVENTION NEWS

Daily PrEP reduces HIV infections by 86% in U.K. PROUD Study

Sex-based PrEP cuts infections by 86%

HIV DRUG DEVELOPMENT NEWS

New form of tenofovir TAF looks to be easier on bone and kidney health to the current TDF

HIV maintenance regimen of cabotegravir and rilpivirine looks promising

Promising results for new HIV attachment inhibitor drug fostemsavir (BMS-663068) as it moves through study

New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat

HIV CARE NEWS

Starting HIV treatment early leads to better health and improved immune systems

Using raltegravir or protease inhibitors influences about equal levels of fat gains

BREATHER Study’s novel dosing regimen of 5 days on/2 days off controls HIV levels in young people

Dutch ATHENA study announces surprising results when using 3TC (lamivudine) over FTC (emtricitabine)

The risk for transmission persists through the first six months of HIV treatment

Smoking greatly increases risk for non-AIDS cancers in people with HIV

Contraceptive implant levorongestrel may not be as effective when taking efavirenz (Sustiva)

Financial incentives don’t increase case linkage or viral suppression

HEPATITIS C NEWS

Adherence to a once-daily medication in hepatitis C mono-infected and HIV/HCV co-infected patients

High SVR rates in HIV/HCV co-infected patients with a fixed-dose regimen of ledipasvir/sofosbuvir

HCV transmission risk factors in HIV-infected MSM

High SVR12 rates seen in HIV/HCV co-infected persons who take daclatasvir with sofosbuvir

The benefits of achieving SVR in HCV mono-Infected and HIV/HCV co-infected persons

Hepatitis C re-infection rates in people after an SVR